TCHP and colorectal carcinoma: Moreover, P53 is known to be mutated in about 50% of CRC and that the mutated state of this tumor suppressor protein is implicated in the increase or decrease of tumor sensitivity to numerous chemotherapeutic drugs (Golstein and Kroemer, 2007; Pires et al., 2016).